Skip to main content

POLARx Post Approval Study (POLARx PAS)

Completed · Not applicable · NCT06170606

Conditions: Paroxysmal Atrial Fibrillation

At a glance

Research payments reported, 2025
$266,639
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
200

About the trial

Sponsor
Boston Scientific Corporation
Tested
Boston Scientific Cardiac Cryoablation System (device)
Dates
Started 2024-06-28; completion 2026-05-20
Results posted
Not yet

To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF).

From ClinicalTrials.gov, last updated 2026-07-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $266,639 in research payments for this study in 2025 (36 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.